Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence

Psychiatry Research

Volumn 167, Issue 1-2, 2009, Pages 115-122

  Muhonen, Leea H ^a,d   Lönnqvist, Jouko ^a,b,c   Lahti, Jari ^b   Alho, Hannu ^a,b,c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Helsinki City Health Center   (Finland)

Author keywords

Alcoholism predictors; Citalopram; Glutamic acid; Major depressive disorder; Serotonin uptake inhibitors

Indexed keywords

ESCITALOPRAM; MEMANTINE;

ADULT; AGED; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE OF ONSET; AGED; ALCOHOLISM; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 64649088504     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.05.001     Document Type: Article

References (36)

1. Angst J., Gamma A., Endrass J., Rossler W., Ajdacic-Gross V., Eich D., Herrell R., and Merikangas K.R. Is the association of alcohol use disorders with major depressive disorder a consequence of undiagnosed bipolar-II disorder?. European Archives of Psychiatry and Clinical Neuroscience 256 (2006) 452-457
2. Anton R.F. Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction 95 Suppl 2 (2000) S211-217
3. Bagby R.M., Ryder A.G., and Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. Journal of Psychiatry and Neuroscience 27 (2002) 250-257
4. Beck A.T., Steer R.A., and Brown G.K. BDI-II, Beck Depression Inventory: Manual. 2nd ed. (1996), Psychological Corporation/Harcourt Brace, San Antonio, TX/Boston
5. Benazzi F., and Akiskal H.S. How best to identify a bipolar-related subtype among major depressive patients without spontaneous hypomania: superiority of age at onset criterion over recurrence and polarity?. Journal of Affective Disorders 107 1-3 (2008) 77-88
6. Cloninger C.R. A systematic method for clinical description and classification of personality variants. A proposal. Archives of General Psychiatry 44 (1987) 573-588
7. Cornelius J.R., Clark D.B., Bukstein O.G., Birmaher B., Salloum I.M., and Brown S.A. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addictive Behaviors 30 (2005) 1824-1833
8. Cornelius J.R., Salloum I.M., Thase M.E., Haskett R.F., Daley D.C., Jones-Barlock A., Upsher C., and Perel J.M. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacology Bulletin 34 (1998) 117-121
9. First M.B., Spitzer R.L., Williams J.B.W., and Gibbon M. Structured Clinical Interview for DSM-IV (SCID) (1995), American Psychiatric Association, Washington
10. Gortelmeyer R., and Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo- controlled study. Arzneimittel-Forschung 42 (1992) 904-913
11. Grant B.F., Stinson F.S., Dawson D.A., Chou S.P., Dufour M.C., Compton W., Pickering R.P., and Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 61 (2004) 807-816
12. Hasin D.S., Stinson F.S., Ogburn E., and Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 64 (2007) 830-842
13. Hays W.L. Statistics (1963), Holt, Rinehart and Winston, Inc., London
14. Klein D.N., Schatzberg A.F., McCullough J.P., Dowling F., Goodman D., Howland R.H., Markowitz J.C., Smith C., Thase M.E., Rush A.J., LaVange L., Harrison W.M., and Keller M.B. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. Journal of Affective Disorders 55 (1999) 149-157
15. Krystal J.H., Petrakis I.L., Limoncelli D., Webb E., Gueorgueva R., D'Souza D.C., Boutros N.N., Trevisan L., and Charney D.S. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 28 (2003) 2020-2028
16. Mark T.L. The costs of treating persons with depression and alcoholism compared with depression alone. Psychiatric Services 54 (2003) 1095-1097
17. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134 (1979) 382-389
18. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M., Lam R.W., Lepine J.P., Moller H.J., Nutt D.J., Rouillon F., Schatzberg A.F., and Thase M.E. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 22 (2007) 323-329
19. Montgomery S.A., Rasmussen J.G., and Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology 8 (1993) 181-188
20. Muhonen L.H., Lonnqvist J., Juva K., and Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Journal of Clinical Psychiatry 69 (2008) 392-399
21. Nunes E.V., and Levin F.R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 291 (2004) 1887-1896
22. Nunes E.V., and Levin F.R. Treating depression in substance abusers. Current Psychiatry Reports 8 (2006) 363-370
23. O'Leary D., Costello F., Gormley N., and Webb M. Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. Journal of Affective Disorders 57 (2000) 159-171
24. Oquendo M.A., Galfalvy H., Russo S., Ellis S.P., Grunebaum M.F., Burke A., and Mann J.J. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. American Journal of Psychiatry 161 (2004) 1433-1441
25. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological Psychiatry 50 (2001) 345-350
26. Papakostas G.I., Petersen T., Homberger C.H., Green C.H., Smith J., Alpert J.E., and Fava M. Hopelessness as a predictor of non- response to fluoxetine in major depressive disorder. Annals of Clinical Psychiatry 19 (2007) 5-8
27. Parker R.D., Flint E.P., Bosworth H.B., Pieper C.F., and Steffens D.C. A three-factor analytic model of the MADRS in geriatric depression. International Journal of Geriatric Psychiatry 18 (2003) 73-77
28. Pirkola S.P., Isometsa E., Suvisaari J., Aro H., Joukamaa M., Poikolainen K., Koskinen S., Aromaa A., and Lonnqvist J.K. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population - results from the Health 2000 Study. Social Psychiatry and Psychiatric Epidemiology 40 (2005) 1-10
29. Sanacora G., Rothman D.L., Mason G., and Krystal J.H. Clinical studies implementing glutamate neurotransmission in mood disorders. Annals of the New York Academy of Sciences 1003 (2003) 292-308
30. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., and Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption - II. Addiction 88 (1993) 791-804
31. Smith D.J., Harrison N., Muir W., and Blackwood D.H. The high prevalence of bipolar spectrum disorders in young adults with recurrent depression: toward an innovative diagnostic framework. Journal of Affective Disorders 84 (2005) 167-178
32. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., and Mendlewicz J. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry 68 (2007) 1062-1070
33. Thase M.E. Managing depressive and anxiety disorders with escitalopram. Expert Opinion Pharmacotherapy 7 (2006) 429-440
34. Tiet Q.Q., and Mausbach B. Treatments for patients with dual diagnosis: a review. Alcoholism, Clinical and Experimental Research 31 (2007) 513-536
35. Zarate Jr. C.A., Singh J.B., Quiroz J.A., De Jesus G., Denicoff K.K., Luckenbaugh D.A., Manji H.K., and Charney D.S. A double- blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 163 (2006) 153-155
36. Zisook S., Lesser I., Stewart J.W., Wisniewski S.R., Balasubramani G.K., Fava M., Gilmer W.S., Dresselhaus T.R., Thase M.E., Nierenberg A.A., Trivedi M.H., and Rush A.J. Effect of age at onset on the course of major depressive disorder. American Journal of Psychiatry 164 (2007) 1539-1546